| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Olverembatinib (GZD824; HQP1351; trade name in China: Nailike) is an orally bioavailable, 3rd generation, and broad spectrum Bcr-Abl inhibitor that received approval in November 2021 in China for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP) harboring the T315I mutation. Bcr-Abl(WT) and Bcr-Abl(T315I) are inhibited by it, with IC50 values of 0.68 nM and 0.34 nM, respectively. With K(d) values of 0.32 and 0.71 nM, respectively, GZD824 bound to Bcr-Abl(WT) and Bcr-Abl(T315I) tightly and strongly inhibited the kinase functions with nanomolar IC(50) values. The Bcr-Abl-positive K562 and Ku812 human CML cells were potently suppressed in their proliferation by GZD824, with IC(50) values of 0.2 and 0.13 nM, respectively. For the purpose of developing Bcr-Abl inhibitors to overcome acquired imatinib resistance, GZD824 is a fresh and promising lead candidate.
| Targets |
Bcr-AblT315I (IC50 = 0.68 nM); Bcr-AblE255K (IC50 = 0.27 nM); Bcr-AblG250E (IC50 = 0.71 nM); Bcr-AblQ252H (IC50 = 0.15 nM); Bcr-AblH396P (IC50 = 0.35 nM); Bcr-AblM351T (IC50 = 0.29 nM); Bcr-AblY253F (IC50 = 0.35 nM); Bcr-AblF317L
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
ABL1, ABL1(E255K), ABL1 (G250E), ABL1(T315I), and ABL1(Y253F) are histidine-tagged full-length human recombinant proteins that are expressed in insect cells. The kinases PV3864, PV3865, PV3866, and PV3863 are P3049. Utilizing the FRET-based Z′-Lyte assay system, inhibitory activities against Abl1 and its mutants are carried out in 384-well plates. In summary, 5 μL of kinase reaction buffer is mixed with the diluted kinase substrate before the kinase is added. Following the delivery of compounds (10 nL) at the indicated concentrations to the reaction via the Echo liquid handler, the mixture is allowed to sit at room temperature for 30 minutes. Following the addition of 5 μL of 2X ATP solution to start the reaction, the mixture is left to sit at room temperature for an additional two hours. The ensuing reactions contain 10 μM of ATP (for wild-type Abl1, and mutants Y253F, Q252H, M351T, and H396P) or 5 μM (for mutants E255K, G250E, and T315I) of Tyr2 Peptide substrate in 50 mM HEPES (PH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.0247 μg/mL Abl1, and inhibitors as needed. Next, add 5 μL of the development reagent, and let the mixture sit at room temperature for two hours before adding 5 μL of the stop solution. With an EnVision Multilabel Reader, the fluorescence signal ratio of 445 nm (Coumarin)/520 nm (fluorescin) is measured. To analyze the data, Graphpad Prism5 is used. The three experiments' mean values make up the data.
|
|
| Cell Assay |
In 96-well culture dishes, cells (Ba/F3 cells expressing wildtype and mutant Bcr-Abl) are plated during the logarithmic phase. Cells are treated with the corresponding compounds or vehicle control at the indicated concentration for 72 hours after the 24-hour mark. After adding 10 μL of CCK-8 per well to the 96-well plates, the cells are incubated for three hours. A microplate reader determines OD450 and OD650. The formula for calculating each well's absorbance rate (A) is OD450 - OD650. Each well's cell viability rate is determined by applying the formula V% = (As – Ac)/(Ab – Ac) × 100%. Graphpad Prism5 was utilized to further analyze the data. The three experiments' mean values make up the data. In the test compound well, As is the absorbance rate; in the well without either the test compound or the cell, Ac is the absorbance rate; and in the well with cell and vehicle control, Ab is the absorbance rate.
|
|
| Animal Protocol |
SCID nude mice, bearing allografted Ba/F3 cells expressing Bcr-AblT315I
1 mg/kg, 2 mg/kg, 5.0 mg/kg, 10 mg/kg, 20 mg/kg Oral gavage, daily, for 10 days |
|
| References |
| Molecular Formula |
C29H27F3N6O
|
|---|---|
| Molecular Weight |
532.22
|
| Exact Mass |
532.22
|
| Elemental Analysis |
C, 65.40; H, 5.11; F, 10.70; N, 15.78; O, 3.00
|
| CAS # |
1257628-77-5
|
| Related CAS # |
Olverembatinib dimesylate;1421783-64-3
|
| Appearance |
White to off-white solid powder
|
| SMILES |
CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4
|
| InChi Key |
TZKBVRDEOITLRB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)
|
| Chemical Name |
4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
|
| Synonyms |
GZD824; Olverembatinib; GZD 824; HQP1351; GZD-824; HQP-1351; Nailike
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8789 mL | 9.3946 mL | 18.7892 mL | |
| 5 mM | 0.3758 mL | 1.8789 mL | 3.7578 mL | |
| 10 mM | 0.1879 mL | 0.9395 mL | 1.8789 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06051409 | Recruiting | Drug: Olverembatinib Drug: Imatinib |
Ph+ ALL | Ascentage Pharma Group Inc. | September 2, 2023 | Phase 3 |
| NCT05311943 | Recruiting | Drug: olverembatinib | Olverembatinib Tyrosine Kinase Inhibitors |
Shenzhen Second People's Hospital | July 1, 2022 | Phase 3 |
| NCT05931757 | Not yet recruiting | Drug: Olverembatinib | Philadelphia-Positive ALL | The First Affiliated Hospital of Soochow University |
July 1, 2023 | Phase 2 |
| NCT05466175 | Not yet recruiting | Drug: Olverembatinib Drug: Prednisone |
Philadelphia-Positive ALL | Chen Suning | October 1, 2022 | Phase 2 |
| NCT05521204 | Recruiting | Drug: Olverembatinib | Myeloproliferative Neoplasm Acute Leukemia |
The First Affiliated Hospital of Soochow University |
September 1, 2022 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA